Skip to main content

Homepage

Education

Education

Explore the intricate landscape of benzodiazepine treatment for anxiety disorders, providing clinicians with essential insights to optimize patient care. Participants will evaluate the nuanced risk-benefit profile of benzodiazepines as a first-line therapy, considering effectiveness, side effects, and long-term outcomes.

News

News

Antidepressant prescribing patterns and outcomes for patients with major depressive disorder (MDD) vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.

News

Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.

News

Patients with tardive dyskinesia (TD) in long-term care (LTC) settings have a high comorbidity and polypharmacy burden, with almost half taking medications that can actually worsen TD

News

Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects, according to a review recently published in the Journal of Neurochemistry.

Videos

Videos
Amber Hoberg, MSN, APRN, PMHNP-BC, discusses the key clinical differences between the 2 FDA-approved treatment options for tardive dyskinesia: deutetrabenazine and valbenazine. Nurse Hoberg provides details on their mechanisms of action, contraindications, and side effects—all important considerations when helping patients find the best medication option for their treatment. For more expert insights on the disorder, visit the Tardive Dyskinesia Excellence Forum.
Videos
In this video, Rakesh Jain, MD, MPH, a distinguished member of the Psych Congress steering committee, details the concept of de-prescribing in psychiatry. Whether preparing for the possible need to adjust medication regimes, or helping patients stop treatment that is no longer needed, “Never, ever enter a war or a battle without an exit plan,” says Dr Jain.

Posters

Posters

It is essential to predict the side effects of concomitant drug use before their clinical complications. To streamline drug prescriptions, we developed a machine-learning pipeline to calibrate the severity of DDIs tailored to psychiatric patients. 

Posters

The Pathway Platform was designed to improve measurement-based care (MBC) and shared decision-making among patients with major depressive disorder (MDD) and primary care providers (PCPs).

Posters

Review of the pharmacology, indications, and safety/tolerability profiles of existing opioid antagonists.